Fate Therapeutics, Inc
Fate Therapeutics is a clinical-stage biopharmaceutical company developing off-the-shelf cellular immunotherapies built from human induced pluripotent stem cells (iPSCs). Its core business is to engineer renewable master cell lines and turn them into uniform T-cell and NK-cell product candidates designed for oncology and autoimmune diseases.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaClinical and preclinical off-the-shelf iPSC-derived cell therapies for cancer and autoimmune disease.
Upfront payments, research funding, and milestone-related revenue from strategic partners.
Grant funding supporting preclinical, IND-enabling, and development activities.
Asiakkaat
Fate does not yet sell approved therapies commercially; its current counterparties are pharmaceutical partners, grant providers, and clinical research collaborators. If its programs succeed, the end customers will be physicians, hospitals, and specialty treatment centers treating patients with hematologic cancers and autoimmune diseases.
Biopharma companies that pay for joint development, access to IP, and milestone-based progress on product candidates.
Public funding sources that support preclinical and IND-enabling work for selected programs.
Hospitals and research centers that enroll patients and generate the clinical data needed for approval.
Autoimmune and oncology specialists who would prescribe approved cell therapies if commercialized.
Hospitals and outpatient centers that would administer off-the-shelf cell therapies after approval.
Strategia
Fate’s strategy is to advance a differentiated iPSC platform into first-in-class or best-in-class off-the-shelf cell therapies, with a near-term focus on FT819 in autoimmune disease. The company is also pursuing regulatory acceleration, broader geographic trial access, and collaboration funding to extend runway while it moves programs toward registrational studies and eventual BLA filing.
This program is the clearest path to value creation and potential first commercial approval.
Broader trial geography can speed enrollment, diversify regulatory pathways, and support global commercialization.
As a clinical-stage company with no product revenue, financing access is essential to sustain development.
Maantiede
The company is headquartered in San Diego, California and conducts substantially all of its operations in the United States. Its current business is primarily U.S.-based, but management has also disclosed plans to expand clinical investigation into the U.K. and EU for FT819, which would broaden regulatory and trial exposure.
Riskit
The company faces the typical clinical-stage biotech risks of trial failure, regulatory delay, and uncertain market acceptance, all of which can prevent commercialization and prolong losses. Its cell-therapy manufacturing process is complex, and the business also depends on access to combination drugs, partner funding, and reimbursement support if any product is approved.
- Clinical development failure or delayVaikutus: KorkeaTodennäköisyys: Korkea
The company has no approved products, so setbacks in trials can eliminate or postpone future revenue.
Kohdistuu: FT819 and other pipeline programs
- Manufacturing and regulatory complexityVaikutus: KorkeaTodennäköisyys: Korkea
iPSC-derived cell therapies require tightly controlled GMP processes and may face additional FDA requirements.
Kohdistuu: Internal GMP production and clinical supply
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company expects meaningful revenue only after approval and must fund operations externally.
Kohdistuu: Operating runway and pipeline continuity
- Market acceptance and reimbursement uncertaintyVaikutus: KorkeaTodennäköisyys: Kohtalainen
Autoimmune patients may be reluctant to accept cell-therapy risk without strong evidence and coverage support.
Kohdistuu: Future commercialization in autoimmune disease
- Dependence on combination-drug accessVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Some programs require monoclonal antibodies or other biologics that must be available on acceptable terms.
Kohdistuu: Clinical trials and future commercial use
Kirjanpito
Harkinnanvaraiset erätRevenue timing depends on performance obligations, research activities, and milestone achievement rather than product sales.
Vaikutus: Can create lumpy quarterly revenue and affect comparability
Management estimates the value of stock price appreciation milestones and similar obligations.
Vaikutus: Changes can affect operating expenses or liabilities
As a development-stage biotech, equity awards are a key part of compensation.
Vaikutus: Affects operating loss and non-cash expense trends
Corporate and GMP facilities create right-of-use assets and lease liabilities.
Vaikutus: Affects balance sheet leverage and operating expense presentation
Management estimates total costs expected under collaboration agreements.
Vaikutus: Can alter accrued expenses and period expense recognition
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Allogene Therapeutics, Inc.
ALLO · Biological Products, (No Diagnostic Substances)
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune disease.
Century Therapeutics, Inc.
IPSC · Biological Products, (No Diagnostic Substances)
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Cabaletta Bio, Inc.
CABA · Biological Products, (No Diagnostic Substances)
Forte Biosciences, Inc.
Pharmaceutical Preparations
Cartesian Therapeutics, Inc.
RNAC · Pharmaceutical Preparations
Päivitetty: 24.9.2026